Short Interest in Astellas Pharma Inc. (OTCMKTS:ALPMY) Expands By 87.2%

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 138,700 shares, a growth of 87.2% from the May 15th total of 74,100 shares. Based on an average daily volume of 647,900 shares, the short-interest ratio is presently 0.2 days.

Astellas Pharma Trading Down 1.8 %

Shares of Astellas Pharma stock opened at $9.79 on Thursday. Astellas Pharma has a 12-month low of $9.15 and a 12-month high of $16.64. The stock has a market capitalization of $17.72 billion, a P/E ratio of 139.86 and a beta of 0.39. The company has a 50-day simple moving average of $9.84 and a 200 day simple moving average of $10.85. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.31.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.11 earnings per share for the quarter. Astellas Pharma had a net margin of 1.20% and a return on equity of 5.85%. The firm had revenue of $2.79 billion for the quarter. Research analysts expect that Astellas Pharma will post 0.36 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.